Wellgistics Health (NASDAQ:WGRX – Get Free Report) and Korro Bio (NASDAQ:KRRO – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.
Profitability
This table compares Wellgistics Health and Korro Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Wellgistics Health | -545.69% | N/A | -145.69% |
| Korro Bio | -1,834.48% | -117.86% | -71.04% |
Valuation and Earnings
This table compares Wellgistics Health and Korro Bio”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Wellgistics Health | $23.34 million | 0.32 | -$101.28 million | ($44.50) | -0.07 |
| Korro Bio | $6.39 million | 29.95 | -$117.26 million | ($11.67) | -1.14 |
Wellgistics Health has higher revenue and earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than Wellgistics Health, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings and price targets for Wellgistics Health and Korro Bio, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Wellgistics Health | 1 | 0 | 0 | 0 | 1.00 |
| Korro Bio | 1 | 2 | 6 | 3 | 2.92 |
Korro Bio has a consensus price target of $16.71, suggesting a potential upside of 25.96%. Given Korro Bio’s stronger consensus rating and higher probable upside, analysts clearly believe Korro Bio is more favorable than Wellgistics Health.
Institutional & Insider Ownership
13.2% of Korro Bio shares are owned by institutional investors. 27.0% of Wellgistics Health shares are owned by insiders. Comparatively, 4.8% of Korro Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
Wellgistics Health has a beta of -1.47, indicating that its share price is 247% less volatile than the S&P 500. Comparatively, Korro Bio has a beta of 3, indicating that its share price is 200% more volatile than the S&P 500.
Summary
Korro Bio beats Wellgistics Health on 9 of the 15 factors compared between the two stocks.
About Wellgistics Health
Founded in 2022, Wellgistics Health is a holding company for various existing and planned strategic businesses centered around pharmaceuticals and healthcare services. As a micro health ecosystem, our portfolio of companies consists of a pharmacy, wholesale operations, and a technology division with a novel platform for hub and clinical services. We are focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. In January 2023 and May 2023, Wellgistics Health entered into separate definitive agreements with the owners of Wood Sage and Wellgistics LLC, respectively, whereby Wellgistics Health would acquire all of the respective outstanding membership interests of Wood Sage and Wellgistics LLC. In June 2024, Wellgistics Health and Wood Sage entered into an amended and revised definitive agreement and closed on the Wood Sage Acquisition, thereby making Wood Sage a wholly owned subsidiary of Wellgistics Health. In connection with the Wood Sage Acquisition, Wellgistics Health acquired Wood Sage’s two operating subsidiaries, APS—a pharmaceutical technology hub—and CSP—a retail community specialty pharmacy. On August 30, 2024, Wellgistics Health closed on the Wellgistics Acquisition, thereby making Wellgistics LLC—a company focused on wholesale operations including the distribution and fulfillment of certain pharmaceutical medications to a network of independent pharmacies meant to improve market access to and patient outcomes regarding the medications—a wholly owned subsidiary of Wellgistics Health. As such, Wellgistics Health currently exists as a holding company with Wood Sage as a directly held intermediate holding company subsidiary, APS and CSP as indirect operating subsidiaries, and Wellgistics LLC as a direct operating subsidiary. On October 4, 2024, the Company changed its corporate name to “Wellgistics Health, Inc.” by filing a duly authorized Certificate of Amendment to its Certificate of Incorporation. Despite that Wellgistics Health only recently closed the Wood Sage Acquisition and the Wellgistics Acquisition during 2024, the three companies have shared common office space, comarketed solutions to the marketplace, and leveraged financial and back-office support prior to June 2024. As such, Wellgistics Health’s management believes that its close business relationships have and will continue to limit the need for post-closing integration. The mailing address of our principal executive office is 3000 Bayport Drive, Suite 950 Tampa, FL.
About Korro Bio
Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Wellgistics Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wellgistics Health and related companies with MarketBeat.com's FREE daily email newsletter.
